Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up

Lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) are FDA- and EMAapproved chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory large B-cell lymphoma (LBCL). However, comparative real-world analyses of their efficacy and toxicity with extended follow-up ar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Haematologica (Roma) Jg. 110; H. 9; S. 2040 - 2054
Hauptverfasser: Portuguese, Andrew J., Huang, Jennifer J., Jeon, Yein, Taheri, Mahnoosh, Albittar, Aya, Liang, Emily C., Hirayama, Alexandre V., Kimble, Erik L., Iovino, Lorenzo, Poh, Christina, Gopal, Ajay K., Shadman, Mazyar, Till, Brian G., Milano, Filippo, Chapuis, Aude G., Otegbeye, Folashade, Cassaday, Ryan D., Basom, Ryan S., Wu, Qian Vicky, Maloney, David G., Gauthier, Jordan
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Italy Fondazione Ferrata Storti 01.09.2025
Ferrata Storti Foundation
Schlagworte:
Adult
Aged
Aged, 80 and over
Antigens, CD19 - therapeutic use
Biological Products
Cell Therapy & Immunotherapy
Female
Follow-Up Studies
Humans
Immunotherapy, Adoptive - adverse effects
Immunotherapy, Adoptive - methods
Lymphoma, Large B-Cell, Diffuse - drug therapy
Lymphoma, Large B-Cell, Diffuse - immunology
Lymphoma, Large B-Cell, Diffuse - mortality
Lymphoma, Large B-Cell, Diffuse - pathology
Lymphoma, Large B-Cell, Diffuse - therapy
Male
Middle Aged
Receptors, Chimeric Antigen
Retrospective Studies
Tissue Extracts - adverse effects
Tissue Extracts - therapeutic use
Treatment Outcome
ISSN:0390-6078, 1592-8721, 1592-8721
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) are FDA- and EMAapproved chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory large B-cell lymphoma (LBCL). However, comparative real-world analyses of their efficacy and toxicity with extended follow-up are lacking. We conducted a retrospective study of 160 LBCL patients treated at the Fred Hutchinson Cancer Center with commercial liso-cel or axi-cel per standard of care. Using inverse probability of treatment weighting (IPTW) to mitigate treatment allocation bias and multivariable adjustments to minimize other sources of confounding, we assessed the impact of CAR T-cell product type on outcomes. Axi-cel was associated with significantly higher rates of cytokine release syndrome (CRS; G1+: adjusted OR [aOR] 4.27, p=0.004; G2+: aOR 2.88, p=0.006), immune effector cell-associated neurotoxicity syndrome (ICANS; G1+: aOR 2.10, p=0.048), and immune effector cell-associated hematotoxicity (ICAHT; G1+: aOR 8.09, p
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
AJP reports consultancy/honoraria from Capvision and Karyopharm Therapeutics. AVH has received research funding from Juno Therapeutics and Nektar Therapeutics; and has received honoraria from Bristol Myers Squibb. AKG has received research funding from Merck, BMS, Gilead Sciences, Seagen, Teva, Pfizer, Janssen Oncology, Millennium, IgM, I-Mab, Takeda, BeiGene, and AstraZeneca; and reports consultancy/honoraria from Pfizer, Seagen, Janssen Oncology, SciTek, Compliment Corporation, Millennium, Gilead Sciences, Nurix, Cellectar, Kite/Gilead, Morphosys/Incyte, I-Mab, TG Therapeutics, Pfizer, ADC therapeutics, Amgen, Actinium Pharmaceuticals, Takeda, Epizyme, and Merck. RDC has received research funding from Amgen, Kite/Gilead, Incyte, Merck, Pfizer, Servier, and Vanda Pharmaceuticals; consultancy/honoraria from Amgen, Autolus, Jazz, Kite/Gilead, and Pfizer; discloses membership on a board or advisory committee for Autolus and PeproMene Bio; and discloses that spouse was employed by and owned stock in Seagen. BGT reports research funding from Mustang Bio and Juno Therapeutics; patents/ royalties from Mustang Bio; and consultancy for Mustang Bio and Proteios Technology. DGM has received research funding from Kite, Juno Therapeutics, Celgene, Legend Biotech, and BMS; honoraria from BMS, Caribou Biosciences, Inc. Celgene, Genentech, Incyte, Juno Therapeutics, Kite, Lily, Mustang Bio, Novartis, and Umoja; and reports membership on a board or advisory committee for A2 Biotherapeutics, Navan Technologies, Chimeric Therapeutics, Genentech, BMS, ImmPACT Bio, Gilead Sciences, Interius, and BMS.
Disclosures
ISSN:0390-6078
1592-8721
1592-8721
DOI:10.3324/haematol.2024.287010